New Pancreatitis Therapies: Current Clinical Trials

In this Mission: Cure patient education webinar, medical experts discuss current clinical trials available to pancreatitis patients.

A clinical trial is a research study to test new treatments on people. It is a critical step in the process of getting a new treatment approved so that it can be given to patients. After a treatment, such as a drug, a diagnostic test, or a procedure, is tested in a lab setting, a clinical trial is designed to test it and make sure that it is effective and safe in humans, and has the desired effect on the condition it is intended to treat. Many drugs never get off the ground because there are not enough volunteers. Don’t let that happen with new pancreatitis treatments.

You have the power to propel research and development toward a cure! Learn more about what is involved in these pancreatitis clinical trials to see if they are right for you.

During this webinar, you will learn about current clinical trials, including:

- The ExoLuminate Study
- The ALLIANCE (Paricalcitol) Clinical Trial
- The SHARP (ERCP) Clinical Trial
- The enrollment process + more

Mission: Cure is working to cure chronic and recurrent acute pancreatitis using impact investing and innovative financing. Our webinars educate patients, families and clinicians about pancreatitis.

To learn more about and get involved with these clinical trials, visit: https://mission-cure.org/new-pancreat...
Subscribe to our mailing list: https://mission-cure.org/join-us/
Visit our website: https://mission-cure.org/
Support us: https://mission-cure.org/donate/
Follow us on Facebook:   / missioncurecp  
Have a look at our Instagram:   / mission_cure  
Find us on Twitter:   / mission_cure  
Join our community on HealthUnlocked: https://healthunlocked.com/pancreatit...
Join our community on Facebook:   / missioncommunity  


Timecodes:

00:00 - Intro
03:57 - What is a clinical trial?
13:21 - ALLIANCE Clinical Trial
22:36 - ExoLuminate Trial
31:52 – SHARP Trial
43:17 – Patient Experience
49:39 – Q&A
57:02 – Closing